At a glance
- Originator Shionogi
- Class Antiglaucomas
- Mechanism of Action Prostaglandin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma